Bragar Eagel & Squire, P.C. Investigates Potential Claims Against Four Major Companies

NEW YORK – In a recent development, the acclaimed shareholder rights law firm Bragar Eagel & Squire, P.C., known for its dedicated advocacy for investors' rights, has initiated an investigation into potential legal claims against a quartet of high-profile corporations. This probe is pertinent to shareholders of Zymeworks Inc. ZYME, Regeneron Pharmaceuticals, Inc. REGN, Jabil Inc. JBL, and DoubleVerify Holdings, Inc. DV. The investigation aims to determine whether these companies have violated securities laws or engaged in other unlawful business practices.

About Regeneron Pharmaceuticals, Inc. REGN

Headquartered in Westchester County, New York, Regeneron Pharmaceuticals, Inc. REGN is a pioneering American biotechnology firm. With an initial focus on neurotrophic factors pivotal for regenerative capabilities—a key inspiration for the company's name—Regeneron has since expanded its research domain to include cytokine and tyrosine kinase receptors, among other biomedical frontiers.

About Jabil Inc. JBL

Jabil Inc. JBL, with corporate headquarters nestled in Saint Petersburg, Florida, provides expansive manufacturing solutions and services on a global scale. The company prides itself on offering adaptable manufacturing capabilities to a diverse client base across a multitude of industries, ensuring efficient and reliable production processes.

About DoubleVerify Holdings, Inc. DV

DoubleVerify Holdings, Inc. DV, positioned at the forefront of digital media accuracy and accountability, delivers a cutting-edge software platform hinging on precision measurement, sophisticated data handling, and thorough analysis. Based in New York, New York, DoubleVerify extends its technological footprint worldwide, showcasing a strong presence in various international locales including Berlin, Tokyo, and London, each contributing to its broad spectrum of digital integrity services.

Investigation, Securities, Shareholders